Cartesian Therapeutics, Inc.
RNAC
$10.50
-$0.07-0.66%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 38.91M | 47.94M | 54.10M | 25.91M | 26.00M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 38.91M | 47.94M | 54.10M | 25.91M | 26.00M |
| Cost of Revenue | 44.91M | 49.85M | 51.45M | 56.57M | 65.66M |
| Gross Profit | -5.99M | -1.91M | 2.65M | -30.67M | -39.66M |
| SG&A Expenses | 29.53M | 38.78M | 38.83M | 37.91M | 34.75M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 74.43M | 88.63M | 90.28M | 94.48M | 100.41M |
| Operating Income | -35.52M | -40.69M | -36.18M | -68.57M | -74.41M |
| Income Before Tax | -77.14M | -263.83M | -248.65M | -273.87M | -238.71M |
| Income Tax Expenses | 287.00K | -19.00M | -19.00M | -19.00M | -19.00M |
| Earnings from Continuing Operations | -77.42 | -244.83 | -229.65 | -254.87 | -219.71 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -77.42M | -244.83M | -229.65M | -254.87M | -219.71M |
| EBIT | -35.52M | -40.69M | -36.18M | -68.57M | -74.41M |
| EBITDA | -34.37M | -39.75M | -35.34M | -67.75M | -73.56M |
| EPS Basic | -10.67 | -50.92 | -51.54 | -54.34 | -48.86 |
| Normalized Basic EPS | -2.20 | -21.41 | -22.24 | -24.05 | -24.77 |
| EPS Diluted | -10.72 | -50.96 | -51.58 | -54.35 | -48.87 |
| Normalized Diluted EPS | -2.22 | -21.43 | -22.26 | -24.05 | -24.77 |
| Average Basic Shares Outstanding | 69.03M | 48.90M | 32.59M | 20.98M | 20.68M |
| Average Diluted Shares Outstanding | 70.10M | 49.97M | 33.66M | 20.98M | 20.68M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |